Inflammatory bowel disease patient-reported quality assessment should drive service improvement: a national survey of UK IBD units and patients.

"Declaration of personal interests: IA received speaker fees from Vifor, Ferring, Takeda and Galapagos; JB received grants from Crohn’s & Colitis UK; KB received honoraria from Thermo Fisher Scientific, Tillots, Dr Falk, Ferring, Bimuno, Norgine, Takeda and Reckitt; MB received grants and travel expenses from Vifor International, Norgine and Tillotts Pharma; ABH received speaker fees from Takeda UK, Ferring and Janssen‐Cilag; CL received research support and/or fees for development and delivery of education from Genentech, Janssen, Takeda, Abbvie, AstraZeneca, Eli Lilly, Orion, Pfizer, Roche, Sanofi Aventis, Ferring, UCB, Dr Falk and Biogen; CPS received unrestricted research grants from Warner Chilcott, Janssen and AbbVie, and provided consultancy or speaker fees from to Warner Chilcott, Dr Falk, AbbVie, Takeda, Fresenius Kabi, Galapagos, MSD, Pfizer, Celltrion, Arena and Janssen; LY has worked with ABBVIE, Falk, Ferring, Galapagos, Tillotts and Takeda in an advisory capacity and received educational support from Ferring."

"FUNDING INFORMATION This work was supported by Crohn's & Colitis UK."